First and only once-daily triple therapy in a single inhaler for adult patients with COPD or ASTHMA
First and only once-daily
triple therapy in a single
inhaler for adult patients
with COPD or ASTHMA

ICS/LABA/LAMA TRELEGY |
ICS/LABA/LAMA BREZTRI7 |
ICS/LABA SYMBICORT8* |
|
---|---|---|---|
One Inhalation, Once a Day | |||
NO Priming or Shaking Required | |||
NO Routine Inhaler Cleaning Required | |||
NO Hand/Breath Coordination Required | |||
FDA-Approved for Both COPD and ASTHMA | |||
Flexible Dosing for ASTHMA—2 Strengths Available |
ICS/LABA/LAMA
TRELEGY
ICS/LABA/LAMA
BREZTRI7
ICS/LABA
SYMBICORT8*
No comparative efficacy or safety conclusions can be drawn from this table.
*US formulation; metered-dose inhaler.
Simplified delivery: 3 medications. 1 inhaler. 1 daily inhalation.

How to Use the TRELEGY ELLIPTA Inhaler
How to Use the TRELEGY ELLIPTA Inhaler
This video demonstrates clearly how to take a dose of TRELEGY. Watch this video with your patients so they can learn how to use the inhaler.
Could once-daily triple therapy in a single inhaler make a difference for your patients?
According to the GOLD Report:
- Use of multiple inhalers for COPD is one factor that may lead to poor inhaler technique9
According to the GINA Report:
- Use of multiple different inhaler types for ASTHMA may lead to confusion for patients and may reduce effective use of inhalers10
TRELEGY does not replace a rescue inhaler. Acute symptoms should be treated with an inhaled SABA.


TRELEGY dosing considerations for patients with COPD or ASTHMA
Instruct ALL patients to:
- Take TRELEGY as 1 inhalation, once daily, at the same time every day
- Use TRELEGY only once every 24 hours
- After inhalation, rinse the mouth with water without swallowing to reduce the risk of oropharyngeal candidiasis
- Treat acute symptoms with an inhaled SABA such as albuterol
No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.
For patients with COPD:
TRELEGY 100/62.5/25 mcg is the only strength indicated for treatment of COPD.
For patients with ASTHMA:
Either strength—100/62.5/25 mcg or 200/62.5/25 mcg—can be the starting dose.
When choosing the starting dose, consider:
- Patients’ disease severity and their previous ASTHMA therapy, including the ICS dosage
- Patients’ current control of ASTHMA symptoms and risk of future exacerbation
For patients who do not respond adequately to TRELEGY 100 once daily, increasing the dose to TRELEGY 200 once daily may provide additional improvement in ASTHMA control. Maximum recommended dosage is 1 inhalation of TRELEGY 200 once daily. For patients who do not respond adequately to TRELEGY 200 once daily, re-evaluate and consider other therapeutic regimens and additional therapeutic options.
For more details:
See Dosage and Administration in the full Prescribing Information.






Demonstrated correct use and rated the ELLIPTA inhaler easy to use1-3
Demonstrated correct use and rated the ELLIPTA inhaler easy to use1-3
Inhalers in study did not contain active ingredient.
Inhaler image is for illustrative purposes only.

Explore the clinical data for once-daily TRELEGY in patients with COPD.